Corona Remedies IPO Allotment LIVE with GMP hinting at a 29% listing gain and online status tracking steps

The pharma company’s IPO was subscribed 137.04 times on the final day of bidding. The ₹655.37-crore issue received bids for 62.65 crore shares against 45,71,882 shares on offer, according to NSE data.

The Corona Remedies IPO allotment has been finalised after witnessing an exceptional overall subscription of 137 times, driven by strong demand from QIBs at 278.52 times, NIIs at 208.88 times, and retail investors at 28.73 times. The ₹655.37-crore issue, priced between ₹1,008 and ₹1,062 per share, attracted heavy bidding, and investors can now check their allotment status on the BSE or Bigshare Services website. Corona Remedies, headquartered in Ahmedabad, manufactures and markets pharmaceutical formulations across multiple therapeutic segments, supported by 71 brands and robust growth in its key revenue-generating products. Meanwhile, the grey market premium has climbed to around ₹305, indicating a potential listing price near ₹1,367—about 29% above the upper price band. The company’s shares are scheduled to list on December 15, 2025, on both NSE and BSE.